Industries > Pharma > Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028

Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028

Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies

PUBLISHED: 18 June 2018
PAGES: 208
PRODUCT CODE: PHA0317

Clear
WOOCS 2.2.1

The Alzheimer’s Disease Therapeutics Market will reach $7.93bn in 2018. The Alzheimer’s Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 12.1% in the second half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 208-page report you will receive 62 tables and 82 figures– all unavailable elsewhere.

The 208-page report provides clear detailed insight into the Alzheimer’s Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Alzheimer’s Disease Market forecasts from 2018-2028, further broken down into:
• Alzheimer’s Drugs Market
• Alzheimer’s Diagnostics Market

• Quantitative analysis of the Alzheimer’s drug market from 2018 to 2028. It includes analysis and forecast of top drugs and pipeline drugs in the market:
• Namenda
• Aricept
• Exelon
• Solanezumab
• Gantenerumab
• Verubecestat

• Quantitative analysis of the Alzheimer’s diagnostics market from 2018-2028. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer’s diagnosis from 2018 to 2028:
• Diagnostic biomarker market
• Others

• Profiles of leading pharma companies involved in developing Alzheimer’s drugs globally. It contains overviews of the companies’ segments, recent mergers and acquisitions and analysis of the companies’ recent financial performances. It also includes the details of the drugs for Alzheimer’s in the pipeline and forecast of the company drugs available in the market:
• Pfizer
• Eisai
• Actavis
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx
• vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer’s disease:
• Eli Lilly
• Amarantus Biosciences Holdings
• Piramal Enterprises
• GE Healthcare
• Navidea
• DiaGenic

• This report also breaks down the revenue forecast for the Alzheimer’s Disease Market by national market:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• Brazil
• India
• Russia

Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028

• This report covers the qualitative analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by visiongain:
• David Hung, Chief Executive Officer of Axovant Sciences Inc.
• Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
• Phyllis Ferrell, Vice President and Alzheimer’s Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028: Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2018-2028


Latest Pharma news

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

READ

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

READ

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

READ

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

READ

Categories